Home » U.S. Drug Administration approves emergency use of Pfizer’s new crown vaccine for 5 to 11-year-olds

U.S. Drug Administration approves emergency use of Pfizer’s new crown vaccine for 5 to 11-year-olds

by admin
</p> <p> U.S. Drug Administration approves emergency use of Pfizer’s new crown <a data-ail="205755" target="_blank" href="https://www.breakinglatest.news/tag/vaccine/" >vaccine</a> for 5 to 11-year-olds<br />

Home> News> e Company

The U.S. Drug Administration approves Pfizer’s new crown vaccine for emergency use in 5 to 11-year-olds

2021-10-30 12:25

Source: Securities Times·e Company

Author: Peng Fei

Securities Times·e Company

Peng Fei

2021-10-30 12:25

Securities Times e Company News, the US Food and Drug Administration issued a statement on the 29th, approving the emergency use of the new crown vaccine jointly developed by Pfizer and German Biotech for the 5 to 11-year-olds. The statement said that the approval of this authorization was based on a “thorough and transparent evaluation” of existing data, including expert opinions from the Independent Advisory Committee of the US Drug Administration. Five to 11-year-old groups receive two doses of Pfizer vaccine, 21 days apart, but the inoculation dose is 10 micrograms per dose, which is one-third of the applicable dose for people aged 12 and above.

Disclaimer: The Securities Times strives to be truthful and accurate. The content mentioned in the article is for reference only and does not constitute substantive investment advice. The operation is at your own risk accordingly.

  • Securities Times APP
  • WeChat public account


  • 3821391

    The U.S. Drug Administration approves Pfizer’s new crown vaccine for emergency use in 5 to 11-year-olds

    6885

    e company

    news

    1445

    Peng Fei

    2021-10-30

    See also  Canada's employment growth in June continues to promote unblocking

    You may also like

    Leave a Comment

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

    Privacy & Cookies Policy